Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)

 Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)

Harbour Annouces Global Partnership with Kelun-Biotech to Develop and Commercialize A167 (Anti-PD-L1 mAb)

Shots:
  • Under the licensing deal Harbour has global rights of A167 (excl. Greater China), to treat multiple solid and hematological cancers
  • Kelun-Biotech will receive an upfront of >$350mn in addition to royalties
  • A167 is under clinical Ph I & II in China targeting lymphoma and solid tumors
Click here to read full press release/ article | Ref: Harbour Biomed | Image:  Business wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post